Related references
Note: Only part of the references are listed.Pregnancy-Related Effects on Tenofovir Pharmacokinetics: a Population Study with 186 Women
Sihem Benaboud et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Pregnancy-Related Effects on Lamivudine Pharmacokinetics in a Population Study with 228 Women
Sihem Benaboud et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
A Comparison of 3 Regimens to Prevent Nevirapine Resistance Mutations in HIV-Infected Pregnant Women Receiving a Single Intrapartum Dose of Nevirapine
Russell B. Van Dyke et al.
CLINICAL INFECTIOUS DISEASES (2012)
Efavirenz Pharmacokinetics During the Third Trimester of Pregnancy and Postpartum
Tim R. Cressey et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2012)
Use of dried blood spots for the determination of plasma concentrations of nevirapine and efavirenz
Wiete Kromdijk et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2012)
Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults
Sherene Min et al.
AIDS (2011)
Thai HIV-1-infected women do not require a dose increase of lopinavir/ritonavir during the third trimester of pregnancy
Reshmie A. Ramautarsing et al.
AIDS (2011)
Pharmacokinetics and Safety of Single-Dose Tenofovir Disoproxil Fumarate and Emtricitabine in HIV-1-Infected Pregnant Women and Their Infants
Patricia M. Flynn et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
Nelfinavir and Its Active Metabolite, Hydroxy-t-Butylamidenelfinavir (M8), Are Transferred in Small Quantities to Breast Milk and Do Not Reach Biologically Significant Concentrations in Breast-Feeding Infants Whose Mothers Are Taking Nelfinavir
Paul J. Weidle et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
Safety and exposure of once-daily ritonavir-boosted atazanavir in HIV-infected pregnant women
F. Conradie et al.
HIV MEDICINE (2011)
Safety and pharmacokinetics of etravirine in pregnant HIV-1-infected women
P. Izurieta et al.
HIV MEDICINE (2011)
Pharmacokinetic profile in late pregnancy and cord blood concentration of tipranavir and enfuvirtide
K. Weizsaecker et al.
INTERNATIONAL JOURNAL OF STD & AIDS (2011)
Atazanavir Pharmacokinetics With and Without Tenofovir During Pregnancy
Mark Mirochnick et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2011)
Clinical Therapeutics in Pregnancy
Maisa N. Feghali et al.
JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY (2011)
Pharmacokinetic Study of Saquinavir 500 mg Plus Ritonavir (1000/100 mg Twice a Day) in HIV-Positive Pregnant Women
Maria Martinez-Rebollar et al.
THERAPEUTIC DRUG MONITORING (2011)
HIV-1 Drug Resistance Emergence among Breastfeeding Infants Born to HIV-Infected Mothers during a Single-Arm Trial of Triple-Antiretroviral Prophylaxis for Prevention of Mother-To-Child Transmission: A Secondary Analysis
Clement Zeh et al.
PLOS MEDICINE (2011)
Pharmacokinetics and virologic response of zidovudine/lopinavir/ritonavir initiated during the third trimester of pregnancy
Tim R. Cressey et al.
AIDS (2010)
Maternal-Fetal Pharmacokinetics and Dynamics of a Single Intrapartum Dose of Maraviroc in Rhesus Macaques
Mark A. Winters et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
Use of newer antiretroviral agents, darunavir and etravirine with or without raltegravir, in pregnancy: a report of two cases
Denise Jaworsky et al.
ANTIVIRAL THERAPY (2010)
Antiretroviral Pharmacology: Special Issues Regarding Pregnant Women and Neonates
Mark Mirochnick et al.
CLINICS IN PERINATOLOGY (2010)
Lopinavir protein binding in HIV-1-infected pregnant women
F. T. Aweeka et al.
HIV MEDICINE (2010)
Suboptimal Nevirapine Steady-State Pharmacokinetics During Intrapartum Compared With Postpartum in HIV-1-Seropositive Ugandan Women
Mohammed Lamorde et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2010)
Lopinavir Tablet Pharmacokinetics With an Increased Dose During Pregnancy
Brookie M. Best et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2010)
Rapid HIV-RNA decline following addition of raltegravir and tenofovir to ongoing highly active antiretroviral therapy in a woman presenting with high-level HIV viraemia at week 38 of pregnancy
Carmela Pinnetti et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2010)
Successful use of darunavir, etravirine, enfuvirtide and tenofovir/emtricitabine in pregnant woman with multiclass HIV resistance
Andre Furco et al.
AIDS (2009)
Efficacy of darunavir despite low plasma trough levels during late pregnancy in an HIV-hepatitis C virus-infected patient
Jerome Pacanowski et al.
AIDS (2009)
Antiretroviral Concentrations in Breast-Feeding Infants of Mothers Receiving Highly Active Antiretroviral Therapy
Mark Mirochnick et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
Early Postpartum Pharmacokinetics of Lopinavir Initiated Intrapartum in Thai Women
Tim R. Cressey et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
A popluation analysis of weight-related differences in lopinavir pharmacokinetics and possible consequences for protease inhibitor-naive and -experienced patients
Marion Bouillon-Pichault et al.
ANTIVIRAL THERAPY (2009)
Population Pharmacokinetics of Tenofovir in HIV-1-Infected Pregnant Women and Their Neonates (ANRS 12109)
D. Hirt et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2009)
Tenofovir disoproxil fumarate in pregnancy and prevention of mother-to-child transmission of HIV-1: is it time to move on from zidovudine?
C. Foster et al.
HIV MEDICINE (2009)
Influence of CYP2B6 polymorphisms on the persistence of plasma nevirapine concentrations following a single intra-partum dose for the prevention of mother to child transmission in HIV-infected Thai women
Soranun Chantarangsu et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2009)
Efficacy of Short-Course AZT Plus 3TC to Reduce Nevirapine Resistance in the Prevention of Mother-to-Child HIV Transmission: A Randomized Clinical Trial
James A. McIntyre et al.
PLOS MEDICINE (2009)
Antiretroviral therapy with a twice-daily regimen containing 400 milligrams of indinavir and 100 milligrams of ritonavir in human immunodeficiency virus type 1-infected women during pregnancy
Jade Ghosn et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
A review of the pharmacokinetics of abacavir
Geoffrey J. Yuen et al.
CLINICAL PHARMACOKINETICS (2008)
Effects of pregnancy on CYP3A and P-glycoprotein activities as measured by disposition of midazolam and digoxin: A University of Washington specialized center of research study
M. F. Hebert et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
Pharmacokinetics and safety of nelfinavir when used in combination with zidovudine and lamivudine in HIV-infected pregnant women: Pediatric AIDS Clinical Trials Group (PACTG) Protocol 353
Y. J. Bryson et al.
HIV CLINICAL TRIALS (2008)
Chronic administration of nevirapine during pregnancy: impact of pregnancy on pharmacokinetics
E. V. Capparelli et al.
HIV MEDICINE (2008)
Efavirenz in human breast milk, mothers', and newborns' plasma
Serge Schneider et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2008)
Lopinavir Exposure With an Increased Dose During Pregnancy
Mark Mirochnick et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2008)
Atazanavir plus low-dose ritonavir in pregnancy: pharmacokinetics and placental transfer
Diego Ripamonti et al.
AIDS (2007)
Steady-state lopinavir levels in third trimester of pregnancy
Fiona Lyons et al.
AIDS (2007)
Pharmacokinetics and safety of indinavir in human immunodeficiency virus-infected pregnant women
Jashvant D. Unadkat et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)
Quantitative immunoassay to measure plasma and intracellular atazanavir levels:: Analysis of drug accumulation in cultured T cells
Camille Roucairol et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)
Response to antiretroviral therapy after a single, peripartum dose of nevirapine
Shahin Lockman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Immunochromatographic strip test for rapid detection of nevirapine in plasma samples from human immunodeficiency virus-infected patients
Tim R. Cressey et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)
A retrospective TDM database analysis of interpatient variability in the pharmacokinetics of lopinavir in HIV-infected adults
Martijn R. van der Leur et al.
THERAPEUTIC DRUG MONITORING (2006)
Pharmacokinetics of nelfinavir in HIV-1-infected pregnant and nonpregnant women
P. Villani et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2006)
Placental transfer and pharmacokinetics of lopinavir and other protease inhibitors in combination with nevirapine at delivery
Andrea Gingelmaier et al.
AIDS (2006)
Comparison of HIV-1 mother-to-child transmission after single-dose nevirapine prophylaxis among African women with subtypes A, C, and D
Susan H. Eshleman et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2006)
Enfurvitide prevents vertical transmission of multidrug-resistant HIV-1 in pregnancy but does not cross the placenta
P Brennan-Benson et al.
AIDS (2006)
Neuropsychiatric complications of antiretroviral therapy
Michelle S. Cespedes et al.
DRUG SAFETY (2006)
Tipranavir - A novel nonpeptidic protease inhibitor of HIV
Jennifer R. King et al.
CLINICAL PHARMACOKINETICS (2006)
Highly active antiretroviral therapy started during pregnancy or postpartum suppresses HIV-1 RNA, but not DNA, in breast milk
RL Shapiro et al.
JOURNAL OF INFECTIOUS DISEASES (2005)
Functional role of P-glycoprotein in the human blood-placental barrier
M Mölsa et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2005)
Low-doses of indinavir boosted with ritonavir in HIV-infected Thai patients: pharmacokinetics, efficacy and tolerability
TR Cressey et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2005)
Nelfinavir and nevirapine side effects during pregnancy
S Timmermans et al.
AIDS (2005)
Temporal changes in drug metabolism (CYP1A2, CYP2D6 and CYP3A activity) during pregnancy
TS Tracy et al.
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY (2005)
Pharmacokinetics of saquinavir plus low-dose ritonavir in human immunodeficiency virus-infected pregnant women
EP Acosta et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2004)
Pharmacokinetics and safety of stavudine in HIV-infected pregnant women and their infants: Pediatric AIDS Clinical Trials Group protocol 332
NA Wade et al.
JOURNAL OF INFECTIOUS DISEASES (2004)
Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy
G Jourdain et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
An enzyme immunoassay for the quantification of plasma and intracellular lopinavir in HIV-infected patients
S Azoulay et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2004)
Maternal-fetal transfer and amniotic fluid accumulation of nucleoside analogue reverse transcriptase inhibitors in human immunodeficiency virus-infected pregnant women
H Chappuy et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2004)
Pharmacokinetics of antiretrovirals in pregnant women
M Mirochnick et al.
CLINICAL PHARMACOKINETICS (2004)
Tenofovir disoproxil fumarate - Clinical pharmacology and pharmacokinetics
BP Kearney et al.
CLINICAL PHARMACOKINETICS (2004)
Pharmacokinetic enhancement of protease inhibitor therapy
JR King et al.
CLINICAL PHARMACOKINETICS (2004)
The cytochrome P4502B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: Implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity
BA Ward et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2003)
Pharmacokinetics of nelfinavir and indinavir in HIV-1-infected pregnant women
BW Kosel et al.
AIDS (2003)
Genetic variations in HLA-B region and hypersensitivity reactions to abacavir
S Hetherington et al.
LANCET (2002)
Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir
S Mallal et al.
LANCET (2002)
Myelomeningocele in a child with intrauterine exposure to efavirenz
C Fundarò et al.
AIDS (2002)
Pharmacokinetics in pregnancy
M Dawes et al.
BEST PRACTICE & RESEARCH IN CLINICAL OBSTETRICS & GYNAECOLOGY (2001)
Circulating metabolites of the human immunodeficiency virus protease inhibitor nelfinavir in humans: Structural identification, levels in plasma, and antiviral activities
KYE Zhang et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2001)
Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients
C Marzolini et al.
AIDS (2001)
Identification of the K103N resistance mutation in Ugandan women receiving nevirapine to prevent HIV-1 vertical transmission
JB Jackson et al.
AIDS (2000)
Pharmacodynamics of human immunodeficiency virus type 1 protease inhibitors
EP Acosta et al.
CLINICAL INFECTIOUS DISEASES (2000)
Pharmacokinetics of indinavir in HIV-positive pregnant women
S Hayashi et al.
AIDS (2000)
Share Paper
